• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NanoViricides, Inc. Common Stock (NY:NNVC)

1.350 -0.010 (-0.74%)
Official Closing Price Updated: 4:10 PM EDT, Oct 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about NanoViricides, Inc. Common Stock

< Previous 1 2 3 4 5 Next >
NanoViricides, Inc. Has Filed its Annual Report
September 30, 2025
Via ACCESS Newswire
RETRANSMISSION: NanoViricides to Present at the Life Science Executive Partnering (LSX) Congress in Boston on September 17, 2025
September 11, 2025
Via ACCESS Newswire
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) to Present at LSX World Congress 2025
September 10, 2025
Via Investor Brand Network
Topics Intellectual Property
NanoViricides to Present at the Life Science Executive Partnering (LSX) Congress in Boston on September 17, 2025
September 09, 2025
Via ACCESS Newswire
NanoViricides Reports NV-387’s Anti-Inflammatory Effects Could Combat Viral-Induced Cancer Resurgence
August 27, 2025
Via AB Newswire
A Drug that Could Reduce Metastatic Cancer Resurgence due to Its Anti-Inflammatory Effects in Viral Infections is in Clinical Trials
August 18, 2025
Via ACCESS Newswire
BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Highlights NV-387 as Potential Treatment for Growing Measles Outbreaks
July 30, 2025
Via Investor Brand Network
Topics Intellectual Property
Measles Cases Increasing Worldwide, Need the New NV-387 Broad-Spectrum Antiviral to Combat, Says NanoViricides
July 30, 2025
Via ACCESS Newswire
BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Highlights NV-387’s Broad Antiviral Potential and Strategic Value for Pandemic Preparedness
July 23, 2025
Via Investor Brand Network
Topics Intellectual Property
NanoViricides Discusses the Multi-Billion-Dollar Potential of Its Broad-Spectrum Drug NV-387; Its Effectiveness Against Influenza, Coronaviruses, RSV, MPox and Now Measles Expected to Drive Value
July 23, 2025
Via ACCESS Newswire
BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Reports Breakthrough Measles Drug Success in Humanized Animal Study
July 21, 2025
Via Investor Brand Network
Topics Intellectual Property
Measles Now Has a Drug - NV-387 Broad-Spectrum Antiviral Successful in Animal Studies, says NanoViricides
July 21, 2025
Via ACCESS Newswire
BioMedNewsBreaks — NanoViricides, Inc. (NYSE American: NNVC) Highlights MPox Drug Progress as WHO Extends Global Health Emergency
July 16, 2025
Via Investor Brand Network
Topics Intellectual Property
WHO Extended Global Emergency Status of MPox Epidemic - Development of Treatment for MPox with NV-387 is Timely, Says NanoViricides
July 16, 2025
Via ACCESS Newswire
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Finalizes Adaptive Trial Design for MPox Drug NV-387
July 14, 2025
Via Investor Brand Network
Topics Intellectual Property
Adaptive Clinical Protocol Design for Phase II MPox Clade I Treatment with a Novel Broad-Spectrum Drug NV-387 is Almost Complete, Reports NanoViricides
July 14, 2025
Via ACCESS Newswire
There is a Strong Business Case for Phase II Clinical Program for Treatment of MPox Infection Using NV-387, an Industry-Leading Broad-Spectrum Antiviral Drug Candidate
July 01, 2025
Via ACCESS Newswire
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Highlights NV-387 as Broad-Spectrum Antiviral Candidate for COVID and Bird Flu Preparedness
June 18, 2025
Via Investor Brand Network
Topics Intellectual Property
With Rising Variants of COVID and Bird Flu, the Single Broad-Spectrum Antiviral NV-387 Would be the Best Partner for Preparedness, Says NanoViricides' Dr. Diwan
June 18, 2025
Via ACCESS Newswire
BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Advances Measles Drug Program Amid Rising Global Outbreaks
June 04, 2025
Via Investor Brand Network
Topics Intellectual Property
NanoViricides Measles Drug Development Animal Study is Imminent
June 04, 2025
Via ACCESS Newswire
NanoViricides (NNVC) to Unveil ‘Escape-Proof’ Antiviral Platform at Major Biotech Convention
June 02, 2025
Via AB Newswire
BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) to Present Breakthrough Antiviral Platform at BIO International Convention
May 28, 2025
Via Investor Brand Network
Topics Intellectual Property
NanoViricides to Present at the BIO International Convention in Boston on Monday, June 16, 2025
May 28, 2025
Via ACCESS Newswire
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Comments on FDA COVID Booster Policy, Highlights Antiviral Strategy
May 22, 2025
Via Investor Brand Network
Topics Intellectual Property
The New Rational FDA COVID Vaccine Policy is Long Overdue, Says NanoViricides' Dr. Diwan
May 22, 2025
Via ACCESS Newswire
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Advances NV-387 Antiviral Program, Prepares for Multiple Phase II Trials
May 16, 2025
Via Investor Brand Network
Topics Intellectual Property
NanoViricides, Inc. Has Filed its Quarterly Report: Broad-Spectrum Antiviral NV-387 To Combat MPox Pandemic in Africa - Phase II Clinical Trial Update, Also Readying to Combat Measles Outbreaks, and to Tackle Bird Flu
May 16, 2025
Via ACCESS Newswire
BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Advances NV-387 Antiviral as Measles and MPox Resurge Globally
May 14, 2025
Via Investor Brand Network
Topics Intellectual Property
Measles Cases Are Increasing Globally; MPox Continues to Be a Threat - Broad-Spectrum Antiviral Drug Could Be the Solution
May 14, 2025
Via ACCESS Newswire
< Previous 1 2 3 4 5 Next >
Recent Quotes
View More
Symbol Price Change (%)
GOOG  246.19
+1.55 (0.63%)
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap